TITLE

Unilabs reports status on Stratify JCV testing

PUB. DATE
March 2013
SOURCE
Medical Device Daily;3/27/2013, Vol. 17 Issue 59, p7
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
This article reports on the two-year testing of Unilabs' CE-marked enzyme-linked immuno sorbent assay (ELISA) test Stratify JCV.
ACCESSION #
86441653

 

Related Articles

  • Multiple sclerosis documentation system (MSDS): moving from documentation to management of MS patients. Ziemssen, Tjalf; Kempcke, Raimar; Eulitz, Marco; GroƟmann, Lars; Suhrbier, Alexander; Thomas, Katja; Schultheiss, Thorsten // Journal of Neural Transmission;Sep2013 Supplement, Vol. 120, p61 

    The long disease duration of multiple sclerosis and the increasing therapeutic options require a individualized therapeutic approach which should be carefully documented over years of observation. To switch from MS documentation to an innovative MS management, new computer- and internet-based...

  • MS disease activity in RESTORE: a randomized 24-week natalizumab treatment interruption study. Magyari, Melinda // Current Medical Literature: Multiple Sclerosis;2014, Vol. 6 Issue 2, p61 

    A review is offered for the article "MS disease activity in RESTORE: a randomized 24-week natalizumab treatment interruption study" by R. J. Fox and colleagues, published in the 2014 issue of the journal "Neurology."

  • Natalizumab withdrawal.  // Reactions Weekly;3/16/2013, Issue 1444, p28 

    The article presents the case of a 50-year-old man with multiple sclerosis (MS), who developed a fulminating MS relapse after stopping natalizumab and that led to death.

  • Natalizumab withdrawal.  // Reactions Weekly;10/20/2012, Issue 1424, p38 

    The article describes the cases of four patients who experienced reactivation of multiple sclerosis (MS) after discontinuing treatment with natalizumab.

  • Natalizumab.  // Reactions Weekly;11/17/2012, Issue 1428, p29 

    The article describes the case of a 49-year-old woman who experienced progressive multifocal leucoencephalopathy while receiving natalizumab treatment for multiple sclerosis.

  • Natalizumab.  // Reactions Weekly;5/12/2012, Issue 1401, p27 

    The article describes the case of a 31-year-old woman who developed severe acute autoimmune hepatitis while receiving natalizumab for multiple sclerosis.

  • Natalizumab withdrawal.  // Reactions Weekly;6/16/2012, Issue 1406, p29 

    The article describes the case of a 28-year-old woman with relapsing-remitting multiple sclerosis (MS) who developed MS relapses following discontinuation of natalizumab treatment.

  • Dramatic worsening following plasma exchange in severe post-natalizumab withdrawal multiple sclerosis relapse.  // Current Medical Literature: Multiple Sclerosis;2012, Vol. 4 Issue 1, p14 

    An abstract of the article "Dramatic worsening following plasma exchange in severe post-natalizumab withdrawal multiple sclerosis relapse," by C. Papeix and colleagues is presented.

  • Lethal multiple sclerosis relapse after natalizumab withdrawal.  // Current Medical Literature: Multiple Sclerosis;2013, Vol. 5 Issue 1, p13 

    A review of the article "Lethal multiple sclerosis relapse after natalizumab withdrawal," by V. Rigua and colleagues, which appeared in the periodical "Neurology" in 2012, is presented.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics